WNKs (with-no-lysine kinases) are the causative genes of a hereditary hypertensive disease, PHAII (pseudohypoaldosteronism type II), and form a signal cascade with OSR1 (oxidative stressresponsive 1)/SPAK (STE20/SPS1-related proline/alanine-rich protein kinase) and Slc12a (solute carrier family 12) transporters. We have shown that this signal cascade regulates blood pressure by controlling vascular tone as well as renal NaCl excretion. Therefore agents that inhibit this signal cascade could be a new class of antihypertensive drugs. Since the binding of WNK to OSR1/SPAK kinases was postulated to be important for signal transduction, we sought to discover inhibitors of WNK/SPAK binding by screening chemical compounds that disrupt the binding. For this purpose, we developed a high-throughput screening method using fluorescent correlation spectroscopy.
WNKs (with-no-lysine kinases) are the causative genes of a hereditary hypertensive disease, PHAII (pseudohypoaldosteronism type II), and form a signal cascade with OSR1 (oxidative stressresponsive 1)/SPAK (STE20/SPS1-related proline/alanine-rich protein kinase) and Slc12a (solute carrier family 12) transporters. We have shown that this signal cascade regulates blood pressure by controlling vascular tone as well as renal NaCl excretion. Therefore agents that inhibit this signal cascade could be a new class of antihypertensive drugs. Since the binding of WNK to OSR1/SPAK kinases was postulated to be important for signal transduction, we sought to discover inhibitors of WNK/SPAK binding by screening chemical compounds that disrupt the binding. For this purpose, we developed a high-throughput screening method using fluorescent correlation spectroscopy.
As a result of screening 17 000 compounds, we discovered two novel compounds that reproducibly disrupted the binding of WNK to SPAK. Both compounds mediated dose-dependent inhibition of hypotonicity-induced activation of WNK, namely the phosphorylation of SPAK and its downstream transporters NKCC1 (Na/K/Cl cotransporter 1) and NCC (NaCl cotransporter) in cultured cell lines. The two compounds could be the promising seeds of new types of antihypertensive drugs, and the method that we developed could be applied as a general screening method to identify compounds that disrupt the binding of two molecules.
INTRODUCTION
PHAII (pseudohypoaldosteronism type II) is an autosomal dominant hereditary hypertensive disease characterized by hyperkalaemia and metabolic acidosis [1] . WNK1 (with-nolysine kinase 1) and WNK4 were identified as the genes responsible for PHAII [2] . Since the discovery of mutations in the WNK1 and WNK4 genes in PHAII, the role of WNKs in the regulation of transporters and channels has been studied in order to elucidate the pathogenic mechanisms of PHAII [3] [4] [5] [6] . On the basis of these observations, WNKs have been attracting attention as new factors controlling human blood pressure. We previously generated Wnk4D561A/ + knock-in mice carrying a heterozygous D561A missense mutation in the Wnk4 gene, which corresponds to the D564A mutation found in PHAII patients [7] , and found increased phosphorylation of the NCC (NaCl cotransporter) and OSR1 (oxidative stress-responsive 1) and SPAK (STE20/SPS1-related proline/alanine-rich protein kinase), which are substrates of WNKs [7] [8] [9] . The increased phosphorylation and activation of NCC caused excessive sodium reabsorption in the distal convoluted tubules in the kidney, which contributes to salt-sensitive hypertension. Previously, the NKCC1 (Na/K/Cl cotransporter 1) phosphorylation cascade in vascular smooth muscle cells was also found to be important for the regulation of vascular tonus [10] [11] [12] . Furthermore, WNK signalling was positively regulated by aldosterone [9] , angiotensin II [13, 14] and insulin [15, 16] . Therefore agents that inhibit this signal cascade could form a new class of antihypertensive drugs that may have dual diuretic and vasodilator effects and might be particularly effective in patients with hyperaldosteronism or hyperinsulinaemia [16, 17] . Protein-protein interactions are of great interest as a tool for drug discovery [18] [19] [20] [21] . To develop WNK signalling inhibitors, we focused on a known binding motif present in both WNK and OSR1/SPAK [22] . In the present study, we sought to discover such drugs by screening chemical compounds that disrupt binding and control signalling. For this purpose, we developed a high-throughput screening method that uses FCS (fluorescent correlation spectroscopy).
MATERIALS AND METHODS

Cell culture and inhibition assay
The murine distal convoluted tubule cell line (mpkDCT) provided by Dr A. Vandewalle (INSERM U773, Université Paris, Paris, France) was cultured in a defined medium as described previously [23] . MOVAS (mouse vascular smooth muscle) cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) FBS, 2 mM Lglutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37
• C in a humidified 5 % CO 2 incubator. mpkDCT cells and MOVAS cells were cultured in six-well dishes. Cells were exposed to various concentrations of compounds for 20 min and stimulated with hypotonic low-chloride medium [24] for 45 min. Cells were lysed by the addition of 0.15 ml of ice-cold lysis buffer [50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 % Triton X-100, 0.27 M sucrose, 1 mM DTT and Complete TM protease
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inhibitor cocktail (Roche) (1 tablet per 50 ml)] to each well. After centrifugation at 12 000 g for 5 min at 4 • C, the supernatants were denatured for 20 min at 60
• C with SDS sample buffer (Cosmo Bio) and subjected to SDS/PAGE.
Immunoblotting
Quantitative immunoblotting was performed as described previously [7] . Blots were probed with the following primary antibodies: anti-(total NCC) [25] , anti-phospho-NCC (pThr 53 ) [9] , anti-(total NKCC1) (Hybridoma Bank), anti-phospho-NKCC1 [26] , anti-(total SPAK) (Cell Signaling Technology), anti-phospho-SPAK [26] and anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Santa Cruz Biotechnology) antibodies. Alkaline phosphatase-conjugated anti-IgG antibodies (Promega) were used as secondary antibodies for immunoblotting. The intensities of the bands were analysed and quantified by ImageJ (NIH) software.
Expression and purification of GST-SPAK-CCT in Escherichia coli
The DNA encoding the residues 452-553 of rat SPAK (CCT, almost identical to residues 442-545 of human SPAK) was cloned into pGEX6P-1 vector. Recombinant GST-fusion SPAK (GST-SPAK-CCT) protein was expressed in BL21 E. coli cells, and 1 litre cultures were grown at 37
• C in 2YT broth [1.6 % (w/v) tryptone/1 % (w/v) yeast extract/0.5 % NaCl] containing 100 μg/ml ampicillin until the attenuance at 600 nm was 0.6. IPTG (1 mM) was then added, and the cells were cultured for an additional 16 h at 28
• C. Cells were isolated by centrifugation and resuspended in 40 ml of ice-cold PBS, followed by sonication (TOMY Ultrasonic Disrupters UD-201). Lysates were centrifuged at 4
• C for 5 min at 10 000 g. The GST-fusion proteins were affinity purified on 1.2 ml glutathione-Sepharose beads and eluted in elution buffer containing 83 mM Tris/HCl, 150 mM KOH and 30 mM glutathione. were prepared (Hokkaido System Science). Recombinant GST-SPAK-CCT was expressed in BL21 E. coli cells and purified using glutathione-Sepharose beads. The TAMRAlabelled peptides were incubated at room temperature (25
• C) for 30 min with various concentrations of GST-SPAK-CCT (1-65 μM) in 1×PBS with 0.05 % Tween 20 reaction buffer, and the FCS measurements of single-molecule fluorescence were performed using the FluoroPoint-light analytical system (Olympus) [27] . The confocal volume to detect fluorescent signals in this equipment is in the range of a single femtolitre. Therefore TAMRA-labelled peptide was diluted so that a single fluorophore was likely to be present in the confocal space. The final concentration of each peptide in the FCS assays was 2.7 nM. The concentration of GST-SPAK-CCT used for screening was 0.5 μM, since at this concentration the binding reaction was not saturated and reproducibly detected (see Figure 1A ). The concentration of DMSO used as a solvent of compounds was 1 % in the final assay solutions.
The assay was performed in a 384-well plate. All experiments were performed in 15 s of data acquisition time, and the 
Biacore analysis
Binding was analysed in a Biacore T100 system. GST-SPAK-CCT was bound to a CM5 sensor chip (pH 4.0, 19 000 response units). The indicated concentrations of compounds in Tris-based buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 and 0.05 % Tween 20) were injected over the immobilized GST-SPAK-CCT for 40 s at a flow rate of 60 μl/min. Interactions between each compound and GST-SPAK-CCT were analysed, and steady-state binding was determined at each concentration. Dissociation of compounds was monitored over 120 s.
Statistical analysis
Statistical significance was evaluated using an unpaired t test. P values <0.05 were considered statistically significant. When more than three groups were compared, one-way ANOVA was used, followed by Fisher's post-hoc test. Data are presented as means + − S.E.M.
RESULTS
Detection of the binding of SPAK to WNK and NCC by FCS
The CCT domain in OSR1/SPAK forms a protein fold that interacts with the Arg-Phe-Xaa-Val/Ile (RFxV/I) motif through a surface-exposed groove. Mutation of each residue within this motif in WNKs abolishes binding to SPAK/OSR1 [22] . The CCT domain functions as a multipurpose docking site, enabling SPAK/OSR1 to interact with substrates (NCC/NKCC1/NKCC2) and activators (WNK1/WNK3/WNK4) [28] [29] [30] . To identify chemical compounds that disrupt this binding, we established a system capable of high-throughput screening to detect the binding of two molecules. FCS is a method capable of measuring the fluctuation rate of a fluorescently labelled single peptide as output of the translational diffusion times. When a fluorescently labelled molecule binds to another molecule, the translational diffusion time is extended by increasing the apparent molecular mass [27] . In accordance with this principle, we first tested whether we could detect the binding of SPAK to WNK and NCC. Fluorescent TAMRA-labelled small peptides containing the RFQV (Arg-Phe-Gln-Val) motif in WNK4 were mixed with the GST-fusion proteins of the CCT domain of SPAK (GST-SPAK-CCT) at various concentrations (2-6.5×10 4 nM) in the wells of 384-well microtiter plates. The translational diffusion time in each well was measured by FluoroPoint-Light (Olympus). The addition of GST-SPAK-CCT dose-dependently increased the translational diffusion time of WNK4-RFQV, indicating that this method could detect binding. The dissociation curve between WNK4 and GST-SPAK-CCT obtained in the FCS assay is shown in Figure 1(A) (apparent K d of 1.3 μM) . Furthermore, to investigate whether WNK1 could also interact with SPAK, we prepared a fluorescent TAMRA-labelled WNK1 peptide (WNK1-RFQV), which shares 59 % amino acid identity with WNK4-RFQV (shown in Supplementary Figure S1 at http://www. biochemj.org/bj/455/bj4550339add.htm). We analysed the interaction of WNK1-RFQV and GST-SPAK-CCT by using FCS, and the results are shown in Figure 1(B) . WNK1-RFQV exhibited almost the same behaviour as WNK4-RFQV (apparent K d of 1.3 μM), indicating that WNK1 interacts with SPAK via the CCT domain similarly to WNK4. In addition, the binding of GST-SPAK-CCT to an RFxV/I motif in NCC, which is the substrate of OSR1/SPAK, was also confirmed in this assay ( Figure 1A , apparent K d of 11.2 μM). The affinity of GST-SPAK-CCT for NCC was 10-fold lower than the affinity for WNK4 and WNK1.
Screening of chemical compounds that disrupt the binding of GST-SPAK-CCT to WNK4
We used this newly developed system to screen 17 000 compounds owned by the Tokyo Medical and Dental University Chemical Biology Screening Center. Since the compounds were dissolved in 1 % DMSO, we first checked whether the FCS assay was affected by DMSO. We confirmed that DMSO at various concentrations from 0.2 % to 10 % (the final concentration used for screening was 1 %) did not affect the diffusion time of either peptide (results not shown). As a positive control indicating the inhibition of interaction between WNK4 peptide and GST-SPAK-CCT, we prepared TAMRA-labelled WNK4 peptide in which the RFXV motif was mutated to AFQV (named WNK4-AFQV), which reportedly did not bind to GST-SPAK-CCT [22] . As expected, WNK4-AFQV did not affect the diffusion time ( Figure 1C ), indicating that it behaved as a positive control of binding inhibition.
Representative results of the initial screening are shown in Figure 2 . Although most of the compounds showed no inhibitory effects, a few compounds restored the diffusion time increased by the binding to GST-SPAK-CCT. We judged that the compound had an inhibitory effect on the binding when the measured Figure S2) , 94 compounds were excluded. Finally, ten secondary hits were obtained.
FCS and Biacore TM assays of two promising compounds
Figure 3(A) shows the chemical structure of the two compounds that showed the highest inhibitory activity among the ten secondary hits (compounds A and B) and one close homologue of compound B that has no inhibitory activity (compound B1). The substance names of compounds A and B are STOCK1S-50699 (PubChem-CID 5749625) and STOCK2S-26016 (PubChem-CID 3135086) respectively. Figure 3(B) shows the results of the in vitro FCS assay of these drugs for the inhibition of the binding of WNK4 and SPAK. The IC 50 values of compound A and B were 37 μM and 16 μM respectively. Furthermore, we tested whether the binding of SPAK to WNK1 as well as WNK4 was inhibited by the same compounds. As shown in Figure 3 (C), the inhibitory effects of both compounds on WNK1 were similar to those for WNK4. Interestingly, compound B1 ( Figure 3A) , a structurally close homologue of compound B, did not show an inhibitory effect in the FCS assay ( Figures 3B and 3C ), suggesting that the inhibitory effect of compound B might not be a non-specific effect on the binding and also provided some implication about the structure-activity relationship of the inhibitor. In the FCS assay, it is difficult to determine whether the compound binds to WNK or SPAK. Thus, to determine the binding partner, we performed further analysis of the interaction between the hit compounds and GST-SPAK-CCT using Biacore TM . As shown in Figure 3 (D), it was confirmed that both compounds bound to GST-SPAK-CCT, although the binding kinetics were different. Compound A showed relatively slow binding and dissociation compared with compound B, which may be a benefit in terms of drug properties. The K d values (steady state) of compounds A and B obtained by the Biacore TM assay were 32 μM and 20 μM respectively. These values were comparable with the values obtained by the FCS assay, clearly suggesting that both hit compounds inhibited the binding of WNK and SPAK by binding to the CCT domain of SPAK.
The two compounds showed inhibitory effects on hypotonicity-induced WNK-SPAK signalling in mpkDCT and MOVAS cells
Next, we tested whether these compounds possess in vivo inhibitory activity for WNK signalling using mpkDCT cells ( Figures 4A and 4C) , which endogenously express SPAK and NCC [28] , and MOVAS cells ( Figures 4B and 4D) , which endogenously express SPAK and NKCC1 [31] . We used 45 min of hypotonic shock (170 mOsm/g H 2 O) to activate WNK signalling. Both compounds A and B dose-dependently inhibited the phosphorylation of endogenous SPAK and NCC in mpkDCT cells and SPAK and NKCC1 in MOVAS cells. To exclude the possibility that the decreases in phosphorylation were due to non-specific effects of the compounds, we evaluated the effect of these compounds on phospho-and total-p38 MAPK (mitogen-activated protein kinase) expression, which is a separate phosphorylation event from WNK-SPAK signalling. As shown in Supplementary Figure S3 (at http://www.biochemj.org/bj/455/ bj4550339add.htm), even with the increased concentrations of the compounds, the phosphorylated p38 expression was not reduced, rather slightly increased by these compounds. Compound B1, a non-inhibitory homologue of compound B, also did not affect the phosphorylation of SPAK and NCC (Supplementary Figure  S4 at http://www.biochemj.org/bj/455/bj4550339add.htm). These data serve as negative controls to support the specificity of the inhibitory effect of compounds A and B on WNK-SPAK signalling.
DISCUSSION
The current interest in therapeutic antibodies vividly demonstrates the value of a strategy to create drugs by disrupting proteinprotein interactions [18] . Therapeutic antibodies have some excellent properties: they are highly specific for their molecular targets, and they tend to be stable in human serum. On the other hand, antibodies are difficult and expensive to manufacture, and they lack oral bioavailability. In addition, antibodies are not cell-permeable; therefore, antagonism of intracellular proteinprotein systems has been limited so far. In this respect, if the target proteins are cytoplasmic proteins, the development of small compounds that disrupt protein-protein interactions is highly anticipated.
We have developed a novel screening system for binding inhibitors using FCS. As shown in Figure 1 , our FCS method succeeded in detecting the binding between WNK and SPAK. Our FCS system has several advantages. First, immobilization of substrates is not required, unlike the Biacore TM system. Secondly, since the assay is performed in aqueous solution, the binding of molecules occurs under more physiological conditions. Thirdly, our system directly assesses the ability of compounds to disrupt the binding of two molecules. Although Biacore TM can detect the binding of compounds to one of the target molecules with high sensitivity, it does not tell us whether the compounds indeed disrupt the binding of two molecules. Furthermore, our system has a great feature capable of high-throughput screening in 384-well plates.
In this FCS system, in order to detect the binding of two molecules the sensitivity would be better when the apparent molecular mass of a fluorophore changes drastically by binding.
Therefore we used TAMRA-labelled WNK peptides as probes. In this respect, their counterpart, SPAK, should be better in the fulllength form than in the partial form (GST-SPAK-CCT). However, the full-length GST-SPAK protein was difficult to obtain in a large amount, mainly due to low solubility and recovery. Thus our binding assay was performed with partial proteins of WNK and SPAK. Therefore we might have missed any compounds that have a greater inhibitory effect on the binding of native full-length proteins. This drawback might be a trade-off for the efficiency of our screening system.
As a result of screening for compounds that disrupt the binding of WNK to SPAK, we obtained two compounds that effectively inhibited the signalling from WNK to NCC and NKCC1 in mpkDCT and MOVAS cells respectively. The amount of total NCC/NKCC1 clearly decreased in the presence of these compounds as the phosphorylation decreased. Similar changes were observed in our previous studies [9, 32] and in WNK4-knockout mice [14] . Recently, we showed that the NCC phosphorylation regulated its ubiquitination [33] , suggesting that the decrease of NCC/NKCC1 phosphorylation would induce the degradation. In this respect, the changes in phosphorylation would be the primary event. Therefore we only presented phosphorylation of NCC/NKCC1 and SPAK data in the histograms of Figure 4 . Nonetheless, it is still possible that our compounds might also block the binding of SPAK to NCC/NKCC1, and the complex formation of SPAK and NCC/NKCC1 might somehow be involved in the stability of the transporters. Further investigation may be necessary on this issue.
The results of the present study clearly demonstrate that the binding between WNK and SPAK is indispensable for WNK signalling in vivo and that these compounds are the promising seeds of a new class of anti-hypertensive drugs with dual actions of diuresis and vasodilation. In addition to the antihypertensive property of a WNK-SPAK signalling inhibitor, the recent advancement of WNK research has revealed the possibility of additional therapeutic targets of WNK-SPAK inhibition. WNK3 stimulated glioma invasion by regulating cell volume through NKCC1 activation [34, 35] . The knockout of SPAK attenuated intestinal inflammation in mice [36, 37] . Those studies suggest the possibility of WNK-SPAK signalling inhibitors that are not just anti-hypertensive drugs. Chemical modification of these compounds would give us better compounds that can be used in vivo.
In conclusion, we developed a new high-throughput screening system to identify compounds that disrupt the binding of two molecules. By using this method, we found promising seeds of WNK signalling inhibitors.
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